Category: Api

Neuland Labs Company Snapshot

Reading Time: 4 minutes Written By: Shuchi.P.Nahar | Twitter Handle: @shuchi_nahar Neuland is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The Company operates in the market using two main business models – Generic Drug Substances (GDS) where they cater to the needs of the Generic players and Custom […]

Animal Health Care Industry Future Ahead..

Reading Time: 7 minutes SHUCHI.P.NAHAR Just like the world around us, animal health has undergone transformational change in the 21st century. Animals are receiving better care, medicines are becoming more targeted, and diseases have even been eradicated. There’s no sign that this change will stop soon. Here are the four trends that will drive animal agriculture and petcare in […]

What is so attractive about CDMO’s in Pharmaceutical Companies?

Reading Time: 6 minutes CDMO’s to be considered as next stepping stone for Pharma Companies… SHUCHI.P.NAHAR Link: In recent years, pharmaceutical outsourcing has grown in popularity amongst drug developers across the industry. Companies are increasingly outsourcing to contract development and manufacturing organisations (CDMOs) due to the benefits outside expertise can bring to their business. So, what are the […]

What will drive pharma sector growth ?

Reading Time: 6 minutes Growth Outlook of Pharmaceutical Sector ! Key Points to Know.. SHUCHI.P.NAHAR The Indian market is impossible to ignore, given its economic prospects. Foreign companies view India as a potential significant contributor of future sales and are ramping up their investments in the country accordingly. India’s domestic market looks promising for global pharma looking to launch […]

Pharmaceutical Industry 10 Years Future Outlook—Opportunity!

Reading Time: 11 minutes Indian Pharmaceutical Industry Outlook Shuchi.P.Nahar The pharmaceutical sector is at a crossroads. In a heavily disrupted marketplace, characterized by shifting payer attitudes and patient empowerment, neither incremental adjustments nor steady evolution are likely to halt the decline of the traditional pharmaceutical business model. This paper looks ahead to a 2030 scenario to examine the trends […]

Back To Top